We Need More Proof That Prenatal Gene Screens Are Beneficial
By The Editors,
Scientific American
| 02. 01. 2016
Untitled Document
Expecting a baby often provokes mixed emotions—wonder and amazement but also concern. Will the child be healthy? Happy? Find his or her spot in the world? Several prenatal blood tests are now available that attempt to ease some of the anxiety—at least about health. By analyzing trace amounts of fetal DNA in a pregnant woman's bloodstream, these tests (which go by such names as Harmony, MaterniT21 PLUS and verifi) can identify various genetic anomalies up to six months before birth. Whether or not parents to be take advantage of these laboratory measures is, of course, up to them. But results from screening tests can be misleading, and industry and federal regulators are not doing enough to ensure that people get all the information they need.
At present, the tests detect major abnormalities—such as three copies of the 21st, 18th or 13th chromosome, which lead, respectively, to Down, Edwards and Patau syndrome. These measures are a definite safety improvement over earlier procedures to check the genes of the unborn. Previously such chromosomal abnormalities could be detected prenatally only by...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...